Open AccessAlogliptin – the new member of DPP-4 inhibitors class
Author(s) -
Нина Александровна Петунина,
Анна Леонтьевна Терехова
Publication year - 2014
Publication title -
obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.154
H-Index - 5
eISSN - 2306-5524
pISSN - 2071-8713
DOI - 10.14341/omet2014425-31
Subject(s) - alogliptin , pioglitazone , glibenclamide , metformin , type 2 diabetes mellitus , medicine , pharmacology , type 2 diabetes , drug class , diabetes mellitus , insulin , endocrinology , drug , sitagliptin
This review presents data on the efficacy and safety of alogliptin, a new representative of the DPP-4 inhibitors, in adult patients with type2 diabetes mellitus (DM type 2) as monotherapy or in combination with metformin, pioglitazone, glibenclamide and insulin.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom